Compton PG - Search Results

1

Clinical efficacy of efalizumab in patients with chronic plaque psoriasis: results from three randomized placebo-controlled Phase III trials: part I.

Pariser DM, Gordon KB, Papp KA, Leonardi CL, Kwon P, Compton PG, Rundle AC, Walicke PA, Lebwohl M. Pariser DM, et al. Among authors: compton pg. J Cutan Med Surg. 2005 Dec;9(6):303-12. doi: 10.1007/s10227-005-0116-1. J Cutan Med Surg. 2005. PMID: 16699904 Review.

2

Safety of efalizumab in patients with moderate to severe chronic plaque psoriasis: review of clinical data. part II.

Papp KA, Camisa C, Stone SP, Caro I, Wang X, Compton P, Walicke PA, Gottlieb AB. Papp KA, et al. J Cutan Med Surg. 2005 Dec;9(6):313-23. doi: 10.1007/s10227-005-0117-0. J Cutan Med Surg. 2005. PMID: 16699903 Review.

3

Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial.

Leonardi CL, Papp KA, Gordon KB, Menter A, Feldman SR, Caro I, Walicke PA, Compton PG, Gottlieb AB; Efalizumab Study Group. Leonardi CL, et al. Among authors: compton pg. J Am Acad Dermatol. 2005 Mar;52(3 Pt 1):425-33. doi: 10.1016/j.jaad.2004.09.029. J Am Acad Dermatol. 2005. PMID: 15761420 Clinical Trial.

4

Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis.

Papp KA, Miller B, Gordon KB, Caro I, Kwon P, Compton PG, Leonardi CL; Efalizumab Study Group. Papp KA, et al. Among authors: compton pg. J Am Acad Dermatol. 2006 Apr;54(4 Suppl 1):S164-70. doi: 10.1016/j.jaad.2005.10.032. J Am Acad Dermatol. 2006. PMID: 16488338 Clinical Trial.

5

An overview of the pharmacokinetics and pharmacodynamics of efalizumab: a monoclonal antibody approved for use in psoriasis.

Joshi A, Bauer R, Kuebler P, White M, Leddy C, Compton P, Garovoy M, Kwon P, Walicke P, Dedrick R. Joshi A, et al. J Clin Pharmacol. 2006 Jan;46(1):10-20. doi: 10.1177/0091270005283282. J Clin Pharmacol. 2006. PMID: 16397279 Review.

6

A review of malignancies observed during efalizumab (Raptiva) clinical trials for plaque psoriasis.

Leonardi CL, Toth D, Cather JC, Langley RG, Werther W, Compton P, Kwon P, Wetherill G, Curtin F, Menter A. Leonardi CL, et al. Dermatology. 2006;213(3):204-14. doi: 10.1159/000095037. Dermatology. 2006. PMID: 17033169

7

Safety of efalizumab therapy in patients with moderate to severe psoriasis: an open-label extension of a phase IIIb trial.

Hamilton T, Menter A, Caro I, Compton P, Sobell J, Papp KA. Hamilton T, et al. Drug Saf. 2008;31(8):715-26. doi: 10.2165/00002018-200831080-00008. Drug Saf. 2008. PMID: 18636790 Clinical Trial.

8

Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: updated results from an ongoing trial.

Gottlieb AB, Hamilton T, Caro I, Kwon P, Compton PG, Leonardi CL; Efalizumab Study Group. Gottlieb AB, et al. Among authors: compton pg. J Am Acad Dermatol. 2006 Apr;54(4 Suppl 1):S154-63. doi: 10.1016/j.jaad.2005.12.018. J Am Acad Dermatol. 2006. PMID: 16488337 Clinical Trial.

9

Population pharmacokinetics of efalizumab (humanized monoclonal anti-CD11a antibody) following long-term subcutaneous weekly dosing in psoriasis subjects.

Sun YN, Lu JF, Joshi A, Compton P, Kwon P, Bruno RA. Sun YN, et al. J Clin Pharmacol. 2005 Apr;45(4):468-76. doi: 10.1177/0091270004272731. J Clin Pharmacol. 2005. PMID: 15778428

10

How much insulin-like growth factor I (IGF-I) circulates? Impact of standardization on IGF-I assay accuracy.

Quarmby V, Quan C, Ling V, Compton P, Canova-Davis E. Quarmby V, et al. J Clin Endocrinol Metab. 1998 Apr;83(4):1211-6. doi: 10.1210/jcem.83.4.4727. J Clin Endocrinol Metab. 1998. PMID: 9543143 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

34 results

Search Page

Filters